EA201370191A1 - КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ - Google Patents

КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA201370191A1
EA201370191A1 EA201370191A EA201370191A EA201370191A1 EA 201370191 A1 EA201370191 A1 EA 201370191A1 EA 201370191 A EA201370191 A EA 201370191A EA 201370191 A EA201370191 A EA 201370191A EA 201370191 A1 EA201370191 A1 EA 201370191A1
Authority
EA
Eurasian Patent Office
Prior art keywords
factor viia
application
compositions containing
coagulation factor
containing modulators
Prior art date
Application number
EA201370191A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид Лаури
Норберт Парро
Original Assignee
Фармасайкликс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармасайкликс, Инк. filed Critical Фармасайкликс, Инк.
Publication of EA201370191A1 publication Critical patent/EA201370191A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201370191A 2007-10-16 2008-10-16 КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ EA201370191A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98038607P 2007-10-16 2007-10-16

Publications (1)

Publication Number Publication Date
EA201370191A1 true EA201370191A1 (ru) 2014-05-30

Family

ID=40568072

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201370191A EA201370191A1 (ru) 2007-10-16 2008-10-16 КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
EA201000633A EA019258B1 (ru) 2007-10-16 2008-10-16 КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201000633A EA019258B1 (ru) 2007-10-16 2008-10-16 КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ

Country Status (9)

Country Link
US (3) US8552046B2 (enExample)
EP (2) EP2209801B1 (enExample)
JP (2) JP5733744B2 (enExample)
KR (1) KR20100093046A (enExample)
CN (2) CN103705507A (enExample)
CA (1) CA2702970A1 (enExample)
EA (2) EA201370191A1 (enExample)
ES (1) ES2403413T3 (enExample)
WO (1) WO2009052323A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100513398C (zh) 2002-12-03 2009-07-15 Axys药物公司 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
JP2008501700A (ja) 2004-06-02 2008-01-24 ファーマサイクリックス，インコーポレイティド 第ＶＩＩａ因子阻害剤
CN103705507A (zh) 2007-10-16 2014-04-09 环状药物公司 凝血因子viia调节剂的制造、组合物和用途
WO2012142317A1 (en) * 2011-04-15 2012-10-18 Gamma Therapeutics, Inc Fast-clotting wound dressings
US8980823B2 (en) 2012-03-07 2015-03-17 Shaker A. Mousa Formulations of Factor VIIa inhibitors and utility
HK1200695A1 (en) 2012-04-16 2015-08-14 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents
CA2917298C (en) * 2013-07-05 2021-06-22 Shaker A. Mousa Novel formulations of factor viia inhibitors and utility
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SG11201702614SA (en) * 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2641058C1 (ru) * 2016-11-17 2018-01-15 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ профилактики венозной тромбоэмболии у больных раком шейки матки
CN109627218B (zh) * 2018-11-27 2022-03-29 深圳市龙华区中心医院 一种抗凝小分子化合物及其应用和包含其的药物
CN116283896B (zh) * 2022-09-07 2024-10-29 广东晨康生物科技有限公司 一种具有pd-l1抑制活性的联苯类化合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
RU2093176C1 (ru) * 1992-12-16 1997-10-20 Левон Никитович Мкртчян Способ лечения рака молочной железы и рака тела матки
HUP0104987A3 (en) 1998-12-18 2002-09-30 Axys Pharmaceuticals Inc South Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
US6465503B2 (en) 2000-08-11 2002-10-15 Axys Pharmaceuticals, Inc. Selective urokinase inhibitors
US20020037912A1 (en) 2000-08-11 2002-03-28 Leahy Ellen M. Factor viia inhibitors
EP1449555B1 (en) * 2001-03-23 2006-06-21 Novo Nordisk A/S Needle cannula
WO2003006670A2 (en) 2001-07-09 2003-01-23 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
EP1474400A1 (en) * 2002-02-13 2004-11-10 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)] -6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
RU2297216C2 (ru) 2002-04-08 2007-04-20 Эм-Джи-Ай Джи-Пи,Инк. Фармацевтические композиции, содержащие растворимые в воде пролекарства пропофола, и способы их применения
CN100513398C (zh) 2002-12-03 2009-07-15 Axys药物公司 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物
AU2003300106A1 (en) 2003-01-08 2004-08-10 Axys Pharmaceuticals, Inc. 2-'5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors
CA2569170A1 (en) * 2004-06-02 2005-12-22 Pharmacyclics, Inc. Factor viia inhibitor
JP2008501700A (ja) * 2004-06-02 2008-01-24 ファーマサイクリックス，インコーポレイティド 第ＶＩＩａ因子阻害剤
CN103705507A (zh) 2007-10-16 2014-04-09 环状药物公司 凝血因子viia调节剂的制造、组合物和用途
US20110299806A1 (en) * 2010-06-08 2011-12-08 Leonid Kashchenevsky Spindle, shaft supporting device and method of supporting a rotatable shaft

Also Published As

Publication number Publication date
EA019258B1 (ru) 2014-02-28
CA2702970A1 (en) 2009-04-23
EP2209801B1 (en) 2013-01-16
JP2015157830A (ja) 2015-09-03
EP2209801A2 (en) 2010-07-28
JP2011500717A (ja) 2011-01-06
CN103705507A (zh) 2014-04-09
EP2586794A3 (en) 2013-07-17
KR20100093046A (ko) 2010-08-24
US8748468B2 (en) 2014-06-10
US20140039022A1 (en) 2014-02-06
JP5733744B2 (ja) 2015-06-10
HK1147267A1 (en) 2011-08-05
US8552046B2 (en) 2013-10-08
CN101861335B (zh) 2013-09-04
CN101861335A (zh) 2010-10-13
US20100298396A1 (en) 2010-11-25
WO2009052323A3 (en) 2009-09-11
EA201000633A1 (ru) 2011-04-29
EP2209801A4 (en) 2011-04-06
US20130158089A1 (en) 2013-06-20
ES2403413T3 (es) 2013-05-17
WO2009052323A2 (en) 2009-04-23
EP2586794A2 (en) 2013-05-01

Similar Documents

Publication Publication Date Title
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
EA201100030A1 (ru) Пиразольные соединения 436
EA201100447A1 (ru) Органические соединения
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
EA201101341A1 (ru) Соединения, ингибирующие киназы, и фармацевтическая композиция на их основе
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
EA200970913A1 (ru) 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов
EA201000633A1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
EA201000113A1 (ru) Пиразольные соединения
EA201100503A1 (ru) Глюкозидные производные и их применения
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
BRPI0920053B8 (pt) composto pirazolilaminopiridina, composição contendo o dito composto e uso do mesmo para tratar câncer
EA201000947A1 (ru) Производные тиазола, применимые в качестве ингибиторов киназы pi3
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
EA201001455A1 (ru) Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3)
MX2012015096A (es) Compuestos heterociclicos fusionados como moduladores del canal ion.
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
MY146087A (en) Tricyclic compound, compositions, and methods
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
MY157116A (en) Novel seh inhibitors and their use
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl